AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Prader-Willi Syndrome

Recent research efforts aimed at curing Prader-Willi Syndrome.

Last updated

Prader-Willi Syndrome

Overview

Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental condition caused by loss of expression of normally active paternal genes in chromosome region 15q11.2–q13; the corresponding maternal genes are usually present but epigenetically silenced, meaning they are switched off by chemical gene-control marks rather than missing DNA. It affects people of all sexes and ancestries and commonly causes severe low muscle tone and feeding difficulty in infancy, followed by developmental differences, hormone deficiencies, behavioral and psychiatric challenges, sleep problems, and eventually hyperphagia—an intense, persistent drive to eat that can lead to life-threatening obesity without a protected food environment. GeneReviews: Prader-Willi Syndrome

There is no established cure. Current care is multidisciplinary and begins early: controlled food access and nutrition planning, physical/developmental therapies, growth hormone and other endocrine treatment when indicated, behavioral and mental-health care, sleep monitoring, and treatment of medical complications. In the United States, diazoxide choline extended-release (Vykat XR) became the first FDA-approved medicine specifically for hyperphagia in PWS on March 26, 2025, but it treats a major symptom rather than restoring the missing genetic program. GeneReviews: Prader-Willi Syndrome FDA orphan-drug record for Vykat XR

Scope of Recent Research (2020–present)

Research activity from 2020 through August 8, 2026 has been substantial, spanning appetite-control drugs, hypothalamus-focused neuroscience, RNA biology, and increasingly direct attempts to reactivate the silent maternal PWS gene region. The central curative question is unusually promising but technically difficult: can researchers safely turn on the intact maternal copy of multiple PWS genes—especially the SNORD116 non-coding RNA cluster—in the right brain cells, at the right developmental time, without disrupting imprinting elsewhere in the genome? The field has reached convincing cellular proof-of-concept for epigenetic reactivation, but no gene-reactivating or gene-replacement treatment has yet entered human clinical trials. Activation of the imprinted PWS locus by CRISPR-based epigenome editing Rescue of imprinted genes by epigenome editing in human cellular models of PWS

Major Breakthroughs and Emerging Therapies

The most direct potential cure strategy is epigenome editing: modifying gene-control marks without necessarily changing the DNA sequence. In 2025, researchers at Duke University, Massachusetts General Hospital, and the Broad Institute used CRISPR-based screening and targeted gene-regulation tools in human induced pluripotent stem cells (iPSCs) to identify regulatory elements controlling the imprinted PWS locus. Their work showed that targeted epigenetic activation can induce expression from the normally silent maternal chromosome, while genome-wide RNA and chromatin analyses were used to assess specificity. Activation of the imprinted PWS locus by CRISPR-based epigenome editing

A separate 2025 study from Keio University and Tokyo Medical University extended this approach in patient-derived iPSCs and neural organoids—three-dimensional stem-cell-derived models of developing brain tissue. Using CRISPR/Cas9-based epigenome editing, the investigators reactivated maternally silenced PWS-region genes and reported widespread demethylation at the targeted maternal locus; edited organoids showed partial correction of PWS-associated gene-expression changes. This is an important molecular breakthrough, but it remains a laboratory result rather than a treatment tested in animals or people. Rescue of imprinted genes by epigenome editing in human cellular models of PWS

A related pharmacologic strategy is to use small molecules that loosen repressive chromatin at the maternal locus. A 2020 study explored combining inhibition of the histone methyltransferase G9a—an enzyme that helps maintain gene silencing—with histamine H3-receptor modulation. The work supported the idea that PWS genes can be pharmacologically reactivated, but such drugs may affect many genes throughout the body, creating a major safety and selectivity challenge before clinical translation. Epigenetics meets GPCR: G9a and histamine H3 receptor inhibition for PWS

Gene and circuit-based approaches are also being explored. In a Magel2-null mouse model relevant to one PWS-region gene, adeno-associated virus (AAV) delivery of brain-derived neurotrophic factor (BDNF) improved a hypothalamic neuroinflammatory signature, building on prior work from the group reporting metabolic and behavioral benefits in the model. This is not replacement of the full PWS genetic region, and MAGEL2-related models do not capture all forms of PWS, but it illustrates a potentially disease-modifying route aimed at hypothalamic dysfunction. AAV-BDNF gene therapy in a Magel2-null PWS model

Researchers are also pursuing RNA-focused strategies because loss of the SNORD116 cluster is strongly implicated in core PWS biology. Studies since 2021 have linked SNORD116 to regulation of RNA stability, RNA splicing, and candidate pathways involving genes such as NHLH2, DGKK, and NLGN3. Australian investigators have additionally funded development of antisense therapy for people with maternal uniparental disomy, a PWS subtype in which both copies of chromosome 15 are maternal. These efforts remain preclinical, but they may help determine which missing transcripts must be restored for a meaningful cure. SNORD116 increases NHLH2 mRNA stability SNORD116 target analyses PWRFA-funded antisense therapy project

Clinical Trials and Experimental Approaches

Most current human trials are symptom-directed rather than curative. Soleno Therapeutics’ diazoxide choline extended-release tablet was studied in the randomized Phase 3 DESTINY PWS trial in 127 participants aged four years and older. The overall primary hyperphagia endpoint was not statistically significant, although a prespecified subgroup with severe hyperphagia showed improvement; longer-term open-label studies reported sustained observations but lack the placebo comparison needed to establish definitive long-term efficacy. The FDA nevertheless approved Vykat XR for hyperphagia in people with PWS aged four years and older in March 2025. DESTINY PWS randomized trial Long-term DCCR open-label study FDA orphan-drug record for Vykat XR

As of August 8, 2026, notable ongoing appetite and obesity trials include Aardvark Therapeutics’ Phase 3 HERO study of oral ARD-101, a placebo-controlled 12-week trial measuring hyperphagia behavior in an estimated 90 participants, and Rhythm Pharmaceuticals’ Phase 2 open-label study of daily injectable setmelanotide in up to 20 people aged 6–65 years with PWS-associated obesity and hyperphagia. These studies may improve management of hunger and weight-related risk, but neither is designed to restore PWS gene expression or cure the syndrome. HERO Phase 3 ARD-101 trial Setmelanotide Phase 2 PWS trial

Methodologies and Scientific Approaches

PWS cure research combines patient-derived iPSCs, differentiated neurons, hypothalamic organoids, genetically engineered mice, and increasingly sophisticated genomic measurements. Researchers use DNA-methylation profiling to measure imprinting, RNA sequencing to determine whether maternal PWS genes have been reactivated, and chromatin-accessibility assays to identify whether editing changes gene regulation outside the intended locus. These approaches are particularly important because PWS is caused by loss of a coordinated imprinted region rather than by a defect in only one conventional protein-coding gene. Activation of the imprinted PWS locus by CRISPR-based epigenome editing Rescue of imprinted genes by epigenome editing in human cellular models of PWS

Other programs focus on identifying measurable biomarkers that can make trials more informative. These include hyperphagia questionnaires, body-composition measurements, hormone and metabolic markers, eye-tracking measures of food attention, spatial gene-expression mapping in human hypothalamus and cerebellum, and models of nutritional phase. Such tools cannot themselves cure PWS, but they may show whether a therapy is reaching the relevant biology before broad clinical outcomes become apparent. FPWR 2025 funded-project archive

Leading Institutions and Funding

Important academic centers include Duke University and its Center for Advanced Genomic Technologies; Massachusetts General Hospital and the Broad Institute; Keio University and Tokyo Medical University in Japan; and laboratories studying PWS at institutions such as the University of Connecticut, University of Florida, and University of Lorraine. Their work spans epigenome editing, SNORD116 biology, hypothalamic circuitry, clinical endocrinology, and trial design. Activation of the imprinted PWS locus by CRISPR-based epigenome editing Rescue of imprinted genes by epigenome editing in human cellular models of PWS SNORD116 target analyses

Patient-led organizations are unusually influential in this small rare-disease field. The Foundation for Prader-Willi Research (FPWR) funded a broad 2025 portfolio that included SNORD116 target discovery, hypothalamic organoids, spatial transcriptomics, SMCHD1-directed reactivation research, and biomarkers; FPWR’s grant program was accepting 2026 letters of intent through September 4, 2026. FPWR UK reported £25,000 awards in 2024 for non-coding RNA research and for behavioral research, while the Prader-Willi Research Foundation Australia has supported antisense and epigenetic-therapy projects. FPWR 2025 funded-project archive FPWR grant program FPWR UK funded research PWRFA-funded projects

Strengths, Limitations, and Challenges

The largest strength of PWS cure research is biological: in many people with PWS, the maternal PWS region is still physically present and potentially recoverable. The 2025 CRISPR-based studies demonstrate that it is possible in human cellular models to awaken parts of this normally silent program, making PWS one of the clearer conceptual candidates for epigenetic restoration therapy. Activation of the imprinted PWS locus by CRISPR-based epigenome editing Rescue of imprinted genes by epigenome editing in human cellular models of PWS

The limitations are formidable. PWS involves several genes and non-coding RNAs, especially SNORD116, whose full functions and necessary dosage remain incompletely defined. A future therapy must reach relevant neurons across the brain, establish durable but controllable expression, avoid immune responses or off-target gene activation, and determine whether restoring genes after birth can reverse developmental changes already established in fetal life or infancy. Symptom trials also show how difficult it is to measure changes in hyperphagia reliably and to translate promising subgroup or open-label results into reproducible benefits. SNORD116 increases NHLH2 mRNA stability SNORD116 target analyses DESTINY PWS randomized trial

Outlook and Future Directions

A true cure for PWS is not close enough to predict a clinical timeline, but the field has moved beyond a purely theoretical goal: maternal-locus reactivation has now been demonstrated in multiple human cellular systems. The next milestones to watch are replication of epigenome-editing results in additional patient genotypes, demonstration of durable benefit and acceptable safety in animal models, development of brain-appropriate delivery systems, and identification of the minimum set of genes or RNAs that must be restored. In parallel, approved and investigational hunger treatments may reduce immediate health risks and improve quality of life while curative genetic strategies mature. Rescue of imprinted genes by epigenome editing in human cellular models of PWS HERO Phase 3 ARD-101 trial Setmelanotide Phase 2 PWS trial

References

Don't see your disease? Request a report